Robert W. Baird Issues Pessimistic Forecast for MiNK Therapeutics (NASDAQ:INKT) Stock Price

MiNK Therapeutics (NASDAQ:INKT) had its price target dropped by investment analysts at Robert W. Baird from $8.00 to $4.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 430.50% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of MiNK Therapeutics in a research report on Wednesday, October 9th.

MiNK Therapeutics Price Performance

MiNK Therapeutics stock opened at $0.75 on Friday. MiNK Therapeutics has a 52 week low of $0.57 and a 52 week high of $1.90. The company’s 50 day moving average price is $0.73 and its two-hundred day moving average price is $0.85.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.